Oral immunization with a live coxsackievirus/HIV recombinant induces Gag p24-specific T cell responses

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-11

  Gu, Rui ^a   Shampang, Anae ^a   Nashar, Toufic ^a   Patil, Manisha ^a   Fuller, Deborah H ^b   Ramsingh, Arlene I ^a  

^a WADSWORTH CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAG PROTEIN P24; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; COXSACKIE VIRUS; CYTOKINE PRODUCTION; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE; VIRUS INFECTIVITY; ANIMAL; BAGG ALBINO MOUSE; ENTEROVIRUS; GENETICS; HUMAN; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; VIROLOGY;

COXSACKIEVIRUS; ENTEROVIRUS; MUS;

ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ENTEROVIRUS B, HUMAN; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 77958551717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012499     Document Type: Article

References (42)

1. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455: 613-619.
2. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, et al. (2008) HIV vaccine research: the way forward. Science 321: 530-532.
3. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760-764.
4. Johnston MI, Fauci AS (2007) An HIV vaccine-evolving concepts. N Engl J Med 356: 2073-2081.
5. Robert-Guroff M (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18: 546-556.
6. Korber BT, Letvin NL, Haynes BF (2009) T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 83: 8300-8314.
7. Uberla K (2008) HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? PLoS Pathog 4(8): e1000114.
8. Letvin NL, Barouch DH, Montefiori DC (2002) Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20: 73-99.
9. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
10. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14: 617-621.
11. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
12. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749-759.
13. Belyakov IM, Ahlers JD (2008) Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine. Trends Immunol 29: 574-585.
14. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI (2007) Vaccination against polio should not be stopped. Nat Rev Microbiol 5: 952-958.
15. Halim SS, Ostrowski SE, Lee WT, Ramsingh AI (2001) Immunogenicity of a foreign peptide expressed within a capsid protein of an attenuated coxsackievirus. Vaccine 19: 958-965.
16. Halim SS, Collins DN, Ramsingh AI (2000) A therapeutic HIV vaccine using coxsackie-HIV recombinants: A possible new strategy. AIDS Res Hum. Retroviruses 16: 1551-1558.
17. Pallansch MA, Roos RP (2007) Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses. In Fields Virology 5th edition Volume 1, ed. DM Knipe, PM Howley, 839-893. Philadelphia: Lippincott Williams & Wilkins.
18. Crotty S, Andino R (2004) Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv Drug Deliv Rev 56: 835-852.
19. Caggana M, Chan P, Ramsingh A (1993) Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype. J Virol 67: 4797-4803.
20. Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, et al. (1988) Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 110: 29-36.
21. Mata M, Paterson Y (1999) Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol 163: 1449-1456.
22. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y (1998) The MHC class Irestricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 161: 2985-2993.
23. Ramsingh AI, Lee WT, Collins DN, Armstrong LE (1997) Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein. J Virol 71: 8690-8697.
24. Ostrowski SE, Reilly AA, Collins DN, Ramsingh AI (2004) Progression or Resolution of Coxsackievirus B4-Induced Pancreatitis - A Genomic Analysis. J Virol 78: 8229-8237.
25. Janeway CA, Travers P, Walport M, Shlomchik MJ (2001) Immunobiology: The Immune System in Health and disease New York: Garland Publishing.
26. Andino R, Silvera D, Suggett SD, Achacoso PL, Miller CJ, et al. (1994) Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265: 1448-1451.
27. Mandl S, Sigal LJ, Rock KL, Andino R (1998) Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci USA 95: 8216-8221.
28. Crotty S, Miller CJ, Lohman BL, Neagu MR, Compton L, et al. (2001) Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 75: 7435-7452.
29. Fultz PN, Stallworth J, Porter D, Novak M, Anderson MJ, et al. (2003) Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease. Virology 315: 425-437.
30. Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, et al. (2009) Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 83: 5087-5100.
31. Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
32. Pallansch MA (1997) Coxsackievirus B epidemiology and public health concerns. Curr Top Microbiol Immunol 223: 13-30.
33. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e3548.
34. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, et al. (2003) Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77: 10780-10789.
35. Stevens R, Lavoy A, Nordone S, Burkhard M, Dean GA (2005) Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine. Vaccine 23: 1479-1490.
36. Huber S, Ramsingh AI (2004) Coxsackievirus-induced Pancreatitis. Viral Immunology 17: 358-369.
37. Huber S (2008) Host immune responses to coxsackievirus B3. Curr Top Microbiol Immunol 323: 199-221.
38. Chapman NM, Ramsingh AI, Tracy S (1997) Genetics of coxsackievirus virulence. Curr Top Microbiol Immunol 223: 227-258.
39. Ramsingh AI (2008) CVB-induced pancreatitis and alterations in gene expression. Curr Top Microbiol Immunol 323: 241-258.
40. Potvin DM, Metzger DW, Lee WT, Collins DN, Ramsingh AI (2003) Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4. J Virol 77: 8272-8279.
41. Gu R, Shampang A, Reilly A, Fisher D, Glass W, et al. (2009) IL-10 is pathogenic during the development of coxsackievirus B4-induced chronic pancreatitis. Virology 395: 77-86.
42. Ramsingh AI, Lee WT, Collins DN, Armstrong LE (1999) T cells contribute to disease severity during coxsackievirus B4 infection. J Virol 73: 3080-3086.